BackChromocell Therapeutics Overview
Chromocell Therapeutics Corp.

Chromocell Therapeutics Return on Equity

Chromocell Therapeutics (CHRO) has a ROE of 4767.29%, above the sector sector average of 11.67%.

Get informed when a big investor buys or sells

+ Follow

ROE

4767.29%

Return on Equity

4767.29%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Chromocell Therapeutics (CHRO) FAQ

As of the most recent data, CHRO shows a ROE of 4767.29%. That is above the sector sector average of 11.67%. Scroll down for historical charts and peer comparison views.

The its sector sector average ROE is about 11.67%. Chromocell Therapeutics is at 4767.29%, which is higher that average. That is roughly 40765.6% above the sector mean. Use the comparison chart on this page to see how CHRO stacks up against individual peers as well.

Check the historical chart to see whether CHRO's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Chromocell Therapeutics with peers to see if the move is company-specific or sector-wide.

Besides this return on equity page, Stockcircle has Chromocell Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 4767.29%) with ownership activity and broader fundamentals.